Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK⁺ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595-3603.

There are errors in Table 2 on page 3597. The daily dose of brentuximab vedotin should read “1.8 mg/kg,” not “1.8 mg/m²,” for cycles 1, 3, and 5 and cycles 2, 4, and 6. In the print and online PDF versions of the article, the daily dose of ifosfamide for cycles 1, 3, and 5 should read “800 mg/m²,” and not “10 mg/m².” The ifosfamide dose was correct in the HTML version at the time of publication. The errors have been corrected in the online version of the article.